Temporomandibular joint (TMJ) disorders affect more than 10 million Americans per year. For many of these patients, the only available treatment is removal of the joint meniscus and there are no clinically effective options for replacement of the meniscus following removal. We are developing Matridisc, an "off-the-shelf" novel device for reconstruction of the TMJ meniscus. It consists of particulate extracellular matrix (ECM) encased within sheets of ECM, to provide a resorbable interpositional "pillow" and an anchoring site to mimic the shape and size of the TMJ meniscus. With the seed funding from Coulter TPII, MatriDisc has become a fully developed and translation ready device in the past year. Currently, this project is preparing for a first-in-man clinical trial which will enable the opportunity to seek additional follow-on funding and commercialization partners.